Árshlutareikningur Sláturfélag Suðurlands jan. – jún. 2025 Reykjavík, 21. ágúst 2025. Fréttatilkynning frá Sláturfélagi Suðurlands svf. Afkoma á fyrri árshelmingi 2025 Tekjur á fyrri árshelmingi 10.131 m.kr. og hækka um 9,4% milli ára694 m.kr. hagnaður á fyrri árshelmingi ársins en 613 m.kr. hagnaður árið áðurEBITDA afkoma var 1.159 m.kr. en 1.103 m.kr. árið áðurEigið fé 8.880 m.kr. í lok júní og eiginfjárhlutfall 60% Árshlutareikningurinn samanstendur af árshlutareikningi Sláturfélags Suðurlands svf. og dó ...

Core Insights - The company reported improved earnings and steady sales growth in Q2 2025, with total sales increasing by 5% year-on-year to DKK 349 million, and organic growth of 3% [1][8] Sales Performance - Sales growth was observed in both B2B and B2C segments, although order intake slowed in the second quarter, particularly in the B2C segment due to weakening consumer confidence and retail spending [2] - The B2B segment saw a decline in project orders, while orders from housebuilders showed a positive trend [2] Financial Metrics - The gross margin increased to 23.7% in Q2 2025, up from 21.5% in Q2 2024, attributed to higher average selling prices and stable input costs [3] - Adjusted EBIT rose by 20% from DKK 28.0 million in Q2 2024 to DKK 33.6 million, with an adjusted EBIT margin of 9.6%, compared to 8.4% in the same period last year [3][8] - Free cash flow improved to DKK 32 million in Q2 2025 from DKK 26 million in Q2 2024, driven by higher earnings and improved net working capital [4][8] Strategic Developments - The company agreed to acquire the remaining 55% of online retailer Celebert ApS, following the majority shareholder's decision to exercise its put option, indicating confidence in Celebert's growth trajectory [5] - Full-year revenue guidance for 2025 has been narrowed to DKK 1,250–1,300 million, with adjusted EBIT expected in the range of DKK 90–110 million [6]

Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage bio ...

Core Viewpoint - Bri-Chem Corp. reported its Q2 2025 financial results, showing a mixed performance with increased sales but challenges in profitability and working capital [1][4]. Financial Performance - Consolidated sales for Q2 2025 were $20.5 million, a 7% increase from $19.1 million in Q2 2024, driven by higher fluid distribution sales in the USA Rockies region [4][5]. - Adjusted EBITDA for Q2 2025 was $1.0 million, up 48% from $706 thousand in Q2 2024, with operating earnings increasing by 24% to $772 thousand [2][8]. - Net earnings for Q2 2025 were $157 thousand, a significant recovery from a net loss of $488 thousand in Q2 2024 [2][5]. - Adjusted net earnings per diluted share improved to $0.01 from a loss of $0.02 in the same period last year [2][5]. Financial Position - Total assets decreased by 10% to $53.4 million from $59.2 million year-over-year [2]. - Working capital fell by 21% to $11.1 million compared to $14.1 million in the previous year, attributed to a decrease in accounts receivables and inventory [5][8]. - Long-term debt slightly decreased by 3% to $6.4 million [2]. Operational Highlights - Canadian drilling fluids distribution sales reached $1.7 million, up by $611 thousand from the previous year, despite a 5% decrease in active operating land rigs [5][6]. - U.S. drilling fluids distribution sales increased by 7% to $12.3 million, with an average of 556 active land rigs, down 4% from the previous year [6][8]. - Canadian blending and packaging sales decreased to $3.9 million, while U.S. sales increased to $2.5 million, reflecting regional activity variations [7][8]. Outlook - The company anticipates a challenging operating environment due to commodity price volatility and cautious capital spending, with drilling activity expected to remain flat or slightly decline [9][10]. - Canadian drilling fluids demand is expected to remain soft through Q3 2025, with potential recovery in Q4 as customers prepare for 2026 drilling programs [11][12]. - U.S. fluid distribution sales are projected to remain stable, supported by sustained activity in key regions [11][12].

Financial Performance - Revenue increased by 47% to $152.7 million compared to $103.8 million in the second quarter of 2024 [9][5] - Collections grew by 85% to $255.7 million, with significant contributions from the United States, which saw a 107.2% increase [4][6] - Estimated Remaining Collections (ERC) rose by 31% to a record $2.9 billion [5][6] - Pre-tax income increased by 82% to $62.0 million, while net income rose by 48% to $47.7 million [5][10] Operational Efficiency - The company achieved a Cash Efficiency Ratio of 75.9%, an improvement of 638 basis points from the previous year [5][30] - Adjusted pre-tax income increased by 55% to $61.7 million [5][32] - Operating expenses rose by 37.3% to $65.5 million, primarily due to increased servicing expenses [10][5] Capital Management - The Board of Directors declared a quarterly cash dividend of $0.24 per share [12][14] - The company invested $125.3 million in acquiring receivable portfolios, a decrease from $140.5 million in the same quarter of 2024 [12][5] - Leverage improved to 1.76x from 2.47x year-over-year, reflecting strong portfolio cash flow growth [13][5] Market Position and Strategy - The investment environment is favorable, characterized by high consumer credit delinquencies and charge-offs, which support portfolio supply [2] - The company is well-positioned with low leverage and ample capital resources to capitalize on upcoming opportunities [2][5] - The CEO highlighted the strong collections growth and record ERC as indicators of the company's competitive advantage [2][5]

Core Insights - BlackRock's Q2 2025 adjusted earnings of $12.05 per share exceeded the Zacks Consensus Estimate of $10.66, marking a 16% increase year-over-year [2] - The company's assets under management (AUM) reached a record high of $12.52 trillion, reflecting an 18% year-over-year growth, driven by net inflows and market appreciation [6] - Despite revenue growth, total expenses rose by 23% year-over-year to $3.69 billion, impacting overall profitability [4] Financial Performance - Net income attributable to BlackRock on a GAAP basis was $1.59 billion, a 7% increase from the prior-year quarter [3] - Revenues for the quarter were $5.42 billion, a 13% year-over-year increase, but slightly below the consensus estimate of $5.43 billion [4] - Non-operating income increased significantly to $521 million from $214 million in the prior-year quarter [5] AUM and Inflows - As of June 30, 2025, AUM totaled $12.52 trillion, with long-term net inflows of $46 billion during the reported quarter [6] - The average AUM for the quarter was $11.97 trillion, reflecting a 15% year-over-year increase [6] Share Repurchases and Outlook - BlackRock repurchased shares worth $375 million in the reported quarter and plans to continue this at least at the same level for the remainder of the year [7][10] - The company anticipates a low teens percentage increase in core G&A expenses for 2025, influenced by the HPS acquisition [8] Acquisition Impact - The HPS acquisition is expected to contribute approximately $450 million in revenue, including $225 million in management fees in Q3 2025 [9] - This deal is projected to positively affect BlackRock's overall effective fee rate by 0.6 basis points [9] Market Sentiment - Recent estimates for BlackRock have shown a downward trend, indicating a potential shift in market sentiment [11][13] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the near term [13]

Financial Performance Highlights - Record H1 2025 revenue reached $967 million, a 23% increase year-over-year, and Adjusted Profit Before Tax was $203 million, up 27% year-over-year[7, 19] - Record Q2 2025 Adjusted Profit Before Tax was $106 million, a 16% increase year-over-year and a 10% sequential increase from Q1[7] - Q2 2025 revenue increased by 18% to $500 million, reflecting diversified revenues[7, 19] - H1 2025 Adjusted Profit Before Tax margin was 21%, an increase of 80 basis points year-over-year[19] - Adjusted Basic EPS for H1 2025 was $2.05, a 21% increase year-over-year[16, 19] Business Segment Performance (Q2 2025) - Clearing revenue increased by 12% to $139 million[21] - Agency and Execution revenue increased significantly by 59% to $261 million[21] - Market Making revenue decreased by 9% to $41 million[21] - Hedging and Investment Solutions revenue decreased by 17% to $6 million[21] Capital and Liquidity - The company issued $500 million in 3-year senior unsecured notes[7] - Private equity shareholder ownership reduced to approximately 17%[7] - Total Funding Sources reached $5.7 billion in June 2025[41] Client Activity and Volumes - Clearing volumes increased by 12% to 3,212 million contracts in Q2 2025[28] - Agency and Execution - Energy volumes increased by 25% to 532 million contracts in Q2 2025[28] - Agency and Execution - Securities volumes increased by 13% to 3,026 million contracts in Q2 2025[28]

Financial Performance - The company's net loss for the third quarter of fiscal 2025 was $17 million, improved from a net loss of $43.6 million in the third quarter of fiscal 2024[10] - Total company adjusted EBITDA for the third quarter of fiscal 2025 was $41 million, a 25% increase from $32.8 million in the prior year[10] - Net total debt decreased by 13% year over year and 2% sequentially to $746 million, with liquidity of $389 million as of June 30, 2025[10] - Consolidated revenue increased by 6% year-over-year[17] - Consolidated adjusted EBITDA margin was 19.1%[17] Salt Segment - Salt sales volumes increased by 4% year over year[10] - Salt segment revenue was $166 million, up 3.4% from $160.6 million in 3Q24[21] - Salt segment adjusted EBITDA was $45.8 million, up 10.1% from $41.6 million in 3Q24[21] - Salt adjusted EBITDA margin was 27.6%, an increase of 1.7 percentage points from 25.9% in 3Q24[21] Plant Nutrition Segment - Plant Nutrition sales volumes increased by 21% year over year, reaching 68 thousand short tons[10, 29] - Plant Nutrition revenue was $44.8 million, up 15.5% from $38.8 million in 3Q24[29] - Plant Nutrition adjusted EBITDA increased to $11.4 million from $7.2 million[29, 31] - Plant Nutrition adjusted EBITDA margin was 25.4%, an increase of 6.9 percentage points from 18.6% in 3Q24[29]

Core Viewpoint - Valneva SE reported strong financial results for the first half of 2025, with total revenues of €97.6 million, a 37.8% increase compared to the same period in 2024, while confirming its financial guidance for the year [5][6][28]. Financial Performance - Total revenues reached €97.6 million in H1 2025, up from €70.8 million in H1 2024, marking a 37.8% increase [6][28]. - Product sales amounted to €91.0 million, a 33.3% increase from €68.3 million in H1 2024 [6][10]. - The company reported a net loss of €20.8 million in H1 2025, compared to a net profit of €34.0 million in H1 2024, which included a one-time gain from the sale of a Priority Review Voucher [6][38]. - Cash and cash equivalents stood at €161.3 million as of June 30, 2025, slightly down from €168.3 million at the end of 2024 [43]. R&D and Regulatory Updates - Valneva is focused on the Phase 3 data readout for its Lyme disease vaccine candidate, VLA15, which is in collaboration with Pfizer [3][19]. - The company has made significant progress in clinical and regulatory areas, including the launch of IXCHIQ® in response to a chikungunya outbreak [7][15]. - IXCHIQ® sales increased to €7.5 million in H1 2025, compared to €1.0 million in H1 2024, benefiting from supply to La Réunion [16][17]. Commercial Developments - Valneva finalized a $32.8 million supply contract for IXIARO® with the U.S. Department of Defense [7][13]. - An exclusive agreement was signed with CSL Seqirus for the marketing and distribution of Valneva's vaccines in Germany [11]. - The company expects product sales to grow to €170-180 million in 2025, contributing to positive cash flow [6][40]. Cost Management - Operating cash burn was significantly reduced to €10.9 million in H1 2025 from €66.3 million in H1 2024, reflecting improved sales and cost management [6][40]. - Research and development expenses increased to €32.4 million in H1 2025, driven by costs related to the Shigella vaccine candidate [32].

Core Viewpoint - Valeura Energy Inc. reported its Q2 2025 financial and operational results, highlighting a strategic focus on growth through redevelopment projects and partnerships while maintaining a strong financial position despite lower oil prices [5][7][12]. Financial Performance - Adjusted Cashflow from Operations for Q2 2025 was US$50.5 million, a decrease of 23% compared to Q2 2024 [8][17]. - Oil production for Q2 2025 was 1.95 million barrels, reflecting a 2% increase from Q2 2024, but a 9% decrease from Q1 2025 [10][12]. - Average realized oil price was US$67.9 per barrel, down 23% from the same period in 2024 [15]. - Revenue from oil sales totaled US$129.3 million, a decline of 21% year-over-year [10][15]. Operational Highlights - The company took a final investment decision on the Wassana field redevelopment project, with construction starting and production expected to begin in Q2 2027 [5][25]. - A strategic farm-in agreement with PTTEP will expand the company's portfolio significantly, increasing gross acreage from 2,623 km² to 22,757 km² [6][31]. - Recent production averaged 23,150 barrels per day in early August 2025, an 8% increase over the Q2 average [20]. Sustainability Efforts - Valeura published its 2024 Sustainability Report, noting a 20% reduction in greenhouse gas emissions intensity compared to the previous year [8][9]. Guidance and Outlook - The company reiterated its 2025 guidance for average daily oil production between 23.0 and 25.5 mbbls/d, and adjusted capex and exploration expenses between US$175 million and US$195 million [29][30].